XML 71 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Operations and Comprehensive Income (Loss) (USD $)
 9 Months Ended 12 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Dec. 31, 2012
Dec. 31, 2011
Revenues:        
Revenue from collaborative research $ 42,015,994 $ 50,283,510 $ 59,645,819 $ 47,054,397
Grant revenue 1,112,238 3,744,047 4,180,279 10,152,969
Total revenues 43,128,232 54,027,557 63,826,098 57,207,366
Costs and expenses:        
Research and development 32,233,828 36,924,987 45,432,894 41,088,899
General and administrative 7,322,974 6,640,740 10,187,894 10,868,791
Total costs and expenses 39,556,802 43,565,727 55,620,788 51,957,690
Income (loss) from operations 3,571,430 10,461,830 8,205,310 5,249,676
Other income (expense) (627,281) 4,752 156,445 1,467,444
Net comprehensive income (loss) $ 2,944,149 $ 10,466,582 $ 8,361,755 $ 6,717,120
Basic net income (loss) per common share $ 0.00 $ 0.00 $ 0.00 $ 0.00
Diluted net income (loss) per common share $ 0.00 $ 0.00 $ 0.00 $ 0.00
Basic weighted average number of common shares 1,463,798 1,078,145 1,083,286 1,025,602
Diluted weighted average number of common shares 21,908,859 21,412,848 1,083,286 1,025,602
Pro forma basic net income (loss) per common share $ 0.16   $ 0.38  
Pro forma diluted net income (loss) per common share $ 0.14   $ 0.38  
Pro forma basic weighted average number of common shares 18,419,588   18,039,142  
Pro forma diluted weighted average number of common shares 20,328,791   21,473,689